Tyra Biosciences (NASDAQ:TYRA) Director Robert More Sells 10,000 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Robert More sold 10,000 shares of Tyra Biosciences stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00. Following the sale, the director owned 3,823,425 shares in the company, valued at approximately $95,585,625. This represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tyra Biosciences Stock Performance

TYRA traded up $2.52 on Friday, reaching $25.51. The company had a trading volume of 2,092,508 shares, compared to its average volume of 499,165. The company has a fifty day moving average of $18.17 and a 200-day moving average of $13.66. Tyra Biosciences, Inc. has a one year low of $6.42 and a one year high of $25.88.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.50). On average, sell-side analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tyra Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of TYRA. Commodore Capital LP raised its holdings in Tyra Biosciences by 8.9% during the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock worth $47,216,000 after buying an additional 275,000 shares during the period. Vestal Point Capital LP increased its position in shares of Tyra Biosciences by 190.9% in the first quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company’s stock worth $26,782,000 after acquiring an additional 1,889,829 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Tyra Biosciences by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock valued at $21,267,000 after acquiring an additional 118,492 shares during the period. Balyasny Asset Management L.P. lifted its position in shares of Tyra Biosciences by 45.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 846,585 shares of the company’s stock valued at $11,844,000 after acquiring an additional 263,199 shares in the last quarter. Finally, Sio Capital Management LLC boosted its stake in Tyra Biosciences by 94.5% in the 2nd quarter. Sio Capital Management LLC now owns 810,274 shares of the company’s stock worth $7,754,000 after purchasing an additional 393,657 shares during the period. Institutional investors and hedge funds own 84.14% of the company’s stock.

Analysts Set New Price Targets

TYRA has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. Raymond James Financial initiated coverage on Tyra Biosciences in a report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 target price on the stock. Wedbush boosted their price target on shares of Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday. Wall Street Zen raised shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $33.17.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.